INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 267 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2022. The put-call ratio across all filers is 0.88 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $94 | +80.8% | 1,372 | +83.9% | 0.00% | – |
| Q1 2024 | $52 | +92.6% | 746 | +96.3% | 0.00% | – |
| Q4 2023 | $27 | +92.9% | 380 | +36.7% | 0.00% | – |
| Q3 2023 | $14 | -36.4% | 278 | -18.7% | 0.00% | – |
| Q2 2023 | $22 | +57.1% | 342 | +31.5% | 0.00% | – |
| Q1 2023 | $14 | +75.0% | 260 | +73.3% | 0.00% | – |
| Q4 2022 | $8 | -99.8% | 150 | +44.2% | 0.00% | – |
| Q3 2022 | $5,000 | 0.0% | 104 | +28.4% | 0.00% | – |
| Q2 2022 | $5,000 | 0.0% | 81 | +1.2% | 0.00% | – |
| Q1 2022 | $5,000 | – | 80 | +1500.0% | 0.00% | – |
| Q4 2021 | $0 | – | 5 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
| Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
| Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
| Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
| Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
| GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
| Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
| WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |